Drug/radiation combo may help shrink established tumors

Aug 25, 2008

Researchers may be closer to understanding why anti-cancer drugs such as Ipilimumab, which boost the tumor-killing power of immune cells, haven't fared well in clinical trials. The new study, which describes a way to enhance the ability of these drugs to shrink well-established tumors, will be published online on August 25th in the Journal of Experimental Medicine.

The immune system's tumor-fighting T cells work best when maximally activated. Scientists have achieved this by blocking molecules that dampen the cells' activation, or by removing a population of regulatory T cells that block the killing ability of tumor-specific T cells. But neither approach has worked well in patients with established tumors.

Combining these two approaches in mice, the new study shows, caused small tumors to shrink but had no effect on large tumors. This finding suggested that some quality of large tumors makes them resistant to T cell killing.

Indeed, the blood vessels around large tumors lacked proteins required for killer T cells to crawl out of the circulation and into the tumor. Combining the T cell-boosting treatment with radiation therapy—which has been shown to increase the expression of these vessel proteins—was effective in shrinking large tumors. It remains to be seen whether combining radiation therapy with T cell-boosting drugs will be effective in humans.

Source: Journal of Experimental Medicine

Explore further: Low risk of malignancy for small complex adnexal masses

add to favorites email to friend print save as pdf

Related Stories

Compact proton therapy for fight against cancer

Jun 10, 2014

The future face of modern-day anti-cancer therapy based on charged particles like protons could potentially involve using laser accelerators. However, these facilities will need to be reduced in terms of ...

Weighing nanoparticles at the attogram scale

Jan 13, 2014

MIT engineers have devised a way to measure the mass of particles with a resolution better than an attogram—one millionth of a trillionth of a gram. Weighing these tiny particles, including both synthetic ...

Hydrogel improves delivery of anti-cancer drug

Nov 01, 2013

The Institute of Bioengineering and Nanotechnology (IBN) and IBM Research (IBM) have developed a new non-toxic hydrogel that is capable of shrinking breast cancer tumors more rapidly than existing therapies. ...

Recommended for you

How does prostate cancer form?

57 minutes ago

Prostate cancer affects more than 23,000 men this year in the USA however the individual genes that initiate prostate cancer formation are poorly understood. Finding an enzyme that regulates this process ...

Low risk of malignancy for small complex adnexal masses

7 hours ago

(HealthDay)—For older women with small complex adnexal masses, the overall risk of malignancy is low, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.